While preclinical evidence supports PARP inhibition [86] (NCT evidence level m3) this was recently shown (NCT02693535) to be ineffective in ATM‐mutated CRC [87] thus not giving it high priority. The gene discussed is ATM; the disease is colorectal carcinoma.